首页 > 最新文献

Cardiovascular Revascularization Medicine最新文献

英文 中文
Intra-arterial nicardipine versus verapamil during transradial access coronary catheterization. 经桡动脉入路冠状动脉导管术中动脉内尼卡地平与维拉帕米的对比。
IF 1.6 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-08-20 DOI: 10.1016/j.carrev.2024.08.008
Keshav Patel, Melissa Duckett, Mladen I Vidovich, Khalil Ibrahim

Introduction: Intra-arterial (IA) vasodilators are recommended during transradial access (TRA) to prevent radial artery spasm (RAS). The American Heart Association (AHA) recommends either IA verapamil, diltiazem, nicardipine, or nitroglycerin to prevent RAS. To our knowledge, the efficacy of RAS prevention and patient tolerability of verapamil and nicardipine has not been directly compared in a randomized fashion.

Methods: We conducted a prospective, single-blinded randomized clinical trial comparing the discomfort experienced by patients receiving either 400 μg of IA nicardipine (n = 26) or 5 mg of IA verapamil (n = 29). Patient discomfort and/or pain was assessed using the Visual Analogue Scale (VAS) both before and after IA administration of nicardipine or verapamil.

Results: There was a statistically significant difference in mean change in VAS scores between the 2 groups, with an average increase in VAS score of 0.88 in the nicardipine group and 4.81 in the verapamil group (p < 0.0001). The overall rate of RAS was low in our study (5.5 %) with no significant difference in RAS incidence between the 2 groups (p = 0.465). The nicardipine group had 2 RAS cases (7.7 %), with 1 requiring a change in strategy (3.8 %). The verapamil group had 1 RAS case (3.4 %) that did not require a change in strategy.

Conclusion: In this trial, we showed that nicardipine causes significantly less discomfort and pain compared to verapamil during IA administration for TRA cardiac catheterization.

导言:建议在经桡动脉入路(TRA)时使用动脉内(IA)血管扩张剂,以防止桡动脉痉挛(RAS)。美国心脏协会(AHA)建议使用维拉帕米、地尔硫卓、尼卡地平或硝酸甘油来预防 RAS。据我们所知,维拉帕米和尼卡地平对 RAS 的预防效果和患者耐受性还没有进行过直接的随机比较:我们进行了一项前瞻性、单盲随机临床试验,比较了接受 400 μg 体内注射尼卡地平(26 人)或 5 mg 体内注射维拉帕米(29 人)的患者的不适感。在服用尼卡地平或维拉帕米前后,均使用视觉模拟量表(VAS)对患者的不适和/或疼痛进行评估:结果:两组 VAS 评分的平均变化差异有统计学意义,尼卡地平组 VAS 评分平均增加 0.88 分,维拉帕米组则平均增加 4.81 分(p 结论:尼卡地平和维拉帕米的疗效均优于尼卡地平:本试验表明,与维拉帕米相比,尼卡地平在 TRA 心导管植入术中引起的不适和疼痛明显更少。
{"title":"Intra-arterial nicardipine versus verapamil during transradial access coronary catheterization.","authors":"Keshav Patel, Melissa Duckett, Mladen I Vidovich, Khalil Ibrahim","doi":"10.1016/j.carrev.2024.08.008","DOIUrl":"https://doi.org/10.1016/j.carrev.2024.08.008","url":null,"abstract":"<p><strong>Introduction: </strong>Intra-arterial (IA) vasodilators are recommended during transradial access (TRA) to prevent radial artery spasm (RAS). The American Heart Association (AHA) recommends either IA verapamil, diltiazem, nicardipine, or nitroglycerin to prevent RAS. To our knowledge, the efficacy of RAS prevention and patient tolerability of verapamil and nicardipine has not been directly compared in a randomized fashion.</p><p><strong>Methods: </strong>We conducted a prospective, single-blinded randomized clinical trial comparing the discomfort experienced by patients receiving either 400 μg of IA nicardipine (n = 26) or 5 mg of IA verapamil (n = 29). Patient discomfort and/or pain was assessed using the Visual Analogue Scale (VAS) both before and after IA administration of nicardipine or verapamil.</p><p><strong>Results: </strong>There was a statistically significant difference in mean change in VAS scores between the 2 groups, with an average increase in VAS score of 0.88 in the nicardipine group and 4.81 in the verapamil group (p < 0.0001). The overall rate of RAS was low in our study (5.5 %) with no significant difference in RAS incidence between the 2 groups (p = 0.465). The nicardipine group had 2 RAS cases (7.7 %), with 1 requiring a change in strategy (3.8 %). The verapamil group had 1 RAS case (3.4 %) that did not require a change in strategy.</p><p><strong>Conclusion: </strong>In this trial, we showed that nicardipine causes significantly less discomfort and pain compared to verapamil during IA administration for TRA cardiac catheterization.</p>","PeriodicalId":47657,"journal":{"name":"Cardiovascular Revascularization Medicine","volume":" ","pages":""},"PeriodicalIF":1.6,"publicationDate":"2024-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142082146","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Outcomes following TAVR in patients with cardiogenic shock: A systematic review and meta-analysis. 心源性休克患者进行 TAVR 后的疗效:系统回顾和荟萃分析。
IF 1.6 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-08-17 DOI: 10.1016/j.carrev.2024.08.002
Ahmad Jabri, Mohammed Ayyad, Maram Albandak, Ahmad Al-Abdouh, Luai Madanat, Basma Badrawy Khalefa, Laith Alhuneafat, Asem Ayyad, Alejandro Lemor, Mohammed Mhanna, Zaid Al Jebaje, Raef Fadel, Pedro Engel Gonzalez, Brian O'Neill, Rodrigo Bagur, Ivan D Hanson, Amr E Abbas, Tiberio Frisoli, James Lee, Dee Dee Wang, Vikas Aggarwal, Khaldoon Alaswad, William W O'Neill, Herbert D Aronow, Mohammad AlQarqaz, Pedro Villablanca

Background: While transcatheter aortic valve replacement (TAVR) has broadened treatment options for critically ill patients, outcomes among those with concomitant cardiogenic shock (CS) are not well-explored.

Methods: We conducted a comprehensive search of major databases for studies comparing outcomes following TAVR in patients with and without CS since inception up to October 31, 2023. Our meta-analysis included five non-randomized observational. Dichotomous outcomes were assessed using the Mantel-Haenszel method (risk ratio, 95 % CI), and continuous outcomes were evaluated using mean difference and 95 % CI with the inverse variance method. Statistical heterogeneity was determined using the inconsistency test (I2).

Results: Among 26,283 patients across five studies, 30-day mortality was higher in the CS group (7267 patients; 27.6 %) compared to those without CS (OR 3.41, 95 % CI [2.01, 5.76], p < 0.01), as well as 30-day major vascular complications (OR 1.72, 95 % CI [1.54, 1.92], p < 0.01). At 1-year follow-up, there was no statistically significant difference in mortality rates between the compared groups (OR 2.68, 95 % CI [0.53, 13.46], p = 0.12). No significant between-group differences were observed in the likelihood of 30-day aortic valve reintervention (OR 3.20, 95 % CI [0.63, 16.22], p = 0.09) or post-TAVR aortic insufficiency (OR 0.91, 95 % CI [0.33, 2.51], p = 0.73). Furthermore, 30-day stroke, pacemaker implantation, and in-hospital major bleeding were comparable between both cohorts.

Conclusion: Among patients undergoing TAVR, short-term mortality is higher but one-year outcomes are similar when comparing those with, to those without, CS. Future studies should examine whether TAVR outcomes are improved when the procedure is delayed to optimize CS and when delay is not possible, whether particular management strategies lead to more favorable periprocedural outcomes.

背景:虽然经导管主动脉瓣置换术(TAVR)拓宽了重症患者的治疗选择,但对伴有心源性休克(CS)的患者的治疗效果还没有进行深入研究:我们对主要数据库进行了全面检索,比较了自 TAVR 开始至 2023 年 10 月 31 日期间有无 CS 患者的治疗效果。我们的荟萃分析包括五项非随机观察性研究。采用曼特尔-海恩泽尔法(风险比、95% CI)评估二分法结果,采用反方差法评估均值差异和95% CI,评估连续性结果。统计异质性采用不一致性检验(I2)确定:在五项研究的26283名患者中,CS组(7267名患者;27.6%)的30天死亡率高于无CS组(OR 3.41,95% CI [2.01,5.76],P 结论:在接受TAVR的患者中,CS组的短期死亡率高于无CS组:在接受 TAVR 的患者中,有 CS 和没有 CS 的患者短期死亡率较高,但一年后的结果相似。未来的研究应探讨当手术延迟以优化 CS 时,TAVR 的预后是否会得到改善;当无法延迟时,特定的管理策略是否会带来更有利的围手术期预后。
{"title":"Outcomes following TAVR in patients with cardiogenic shock: A systematic review and meta-analysis.","authors":"Ahmad Jabri, Mohammed Ayyad, Maram Albandak, Ahmad Al-Abdouh, Luai Madanat, Basma Badrawy Khalefa, Laith Alhuneafat, Asem Ayyad, Alejandro Lemor, Mohammed Mhanna, Zaid Al Jebaje, Raef Fadel, Pedro Engel Gonzalez, Brian O'Neill, Rodrigo Bagur, Ivan D Hanson, Amr E Abbas, Tiberio Frisoli, James Lee, Dee Dee Wang, Vikas Aggarwal, Khaldoon Alaswad, William W O'Neill, Herbert D Aronow, Mohammad AlQarqaz, Pedro Villablanca","doi":"10.1016/j.carrev.2024.08.002","DOIUrl":"https://doi.org/10.1016/j.carrev.2024.08.002","url":null,"abstract":"<p><strong>Background: </strong>While transcatheter aortic valve replacement (TAVR) has broadened treatment options for critically ill patients, outcomes among those with concomitant cardiogenic shock (CS) are not well-explored.</p><p><strong>Methods: </strong>We conducted a comprehensive search of major databases for studies comparing outcomes following TAVR in patients with and without CS since inception up to October 31, 2023. Our meta-analysis included five non-randomized observational. Dichotomous outcomes were assessed using the Mantel-Haenszel method (risk ratio, 95 % CI), and continuous outcomes were evaluated using mean difference and 95 % CI with the inverse variance method. Statistical heterogeneity was determined using the inconsistency test (I<sup>2</sup>).</p><p><strong>Results: </strong>Among 26,283 patients across five studies, 30-day mortality was higher in the CS group (7267 patients; 27.6 %) compared to those without CS (OR 3.41, 95 % CI [2.01, 5.76], p < 0.01), as well as 30-day major vascular complications (OR 1.72, 95 % CI [1.54, 1.92], p < 0.01). At 1-year follow-up, there was no statistically significant difference in mortality rates between the compared groups (OR 2.68, 95 % CI [0.53, 13.46], p = 0.12). No significant between-group differences were observed in the likelihood of 30-day aortic valve reintervention (OR 3.20, 95 % CI [0.63, 16.22], p = 0.09) or post-TAVR aortic insufficiency (OR 0.91, 95 % CI [0.33, 2.51], p = 0.73). Furthermore, 30-day stroke, pacemaker implantation, and in-hospital major bleeding were comparable between both cohorts.</p><p><strong>Conclusion: </strong>Among patients undergoing TAVR, short-term mortality is higher but one-year outcomes are similar when comparing those with, to those without, CS. Future studies should examine whether TAVR outcomes are improved when the procedure is delayed to optimize CS and when delay is not possible, whether particular management strategies lead to more favorable periprocedural outcomes.</p>","PeriodicalId":47657,"journal":{"name":"Cardiovascular Revascularization Medicine","volume":" ","pages":""},"PeriodicalIF":1.6,"publicationDate":"2024-08-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142113458","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Palliative care consultation in patients hospitalized with out-of-hospital cardiac arrest: Impact on invasive procedures, do-not-resuscitate orders, and healthcare costs. 院外心脏骤停住院患者的姑息治疗咨询:对侵入性程序、拒绝复苏指令和医疗成本的影响。
IF 1.6 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-08-17 DOI: 10.1016/j.carrev.2024.08.003
Abdilahi Mohamoud, Nadhem Abdallah, Abdirahman Wardhere, Mahmoud Ismayl

Background: The impact of palliative care consultation on the management and outcomes of patients hospitalized with out-of-hospital cardiac arrest (OHCA) remains poorly understood. This study examined associations between palliative care consultation and in-hospital outcomes of patients hospitalized with OHCA, stratified by survival status.

Method: This cross-sectional study used data from the National Inpatient Sample (2016-2021). Adult patients hospitalized with OHCA who received cardiopulmonary resuscitation were included. Multivariable analyses assessed associations between palliative care consultation and outcomes in non-terminal and terminal OHCA hospitalizations, adjusting for demographics, hospital characteristics, and comorbidities.

Results: Among 488,700 OHCA hospitalizations, palliative care consultation was associated with lower odds of invasive procedures in non-terminal hospitalizations, including percutaneous coronary intervention (PCI) (aOR 0.30, 95 % CI 0.25-0.36), mechanical circulatory support (aOR 0.54, 95 % CI 0.44-0.68), permanent pacemaker (aOR 0.27, 95 % CI 0.20-0.37), implantable cardioverter defibrillator insertion (aOR 0.22, 95 % CI 0.16-0.31), and cardioversion (aOR 0.62, 95 % CI 0.55-0.70). In terminal hospitalizations, palliative care was associated with lower odds of PCI (aOR 0.78, 95 % CI 0.70-0.87) and cardioversion (aOR 0.91, 95 % CI 0.85-0.97), but higher odds of therapeutic hypothermia (aOR 3.12, 95 % CI 2.72-3.59), gastrostomy (aOR 1.22, 95 % CI 1.05-1.41), and renal replacement therapy (aOR 1.19, 95 % CI 1.12-1.26). Palliative care was associated with higher DNR utilization in both subgroups and lower hospital costs in non-terminal hospitalizations but higher costs in terminal hospitalizations.

Conclusion: Palliative care consultation in OHCA is associated with differences in invasive procedures, DNR utilization, and hospital costs, varying by survival status.

背景:姑息关怀咨询对院外心脏骤停(OHCA)住院患者的管理和预后的影响仍鲜为人知。本研究探讨了姑息治疗咨询与OHCA住院患者的院内预后之间的关系,并根据生存状况进行了分层:这项横断面研究使用了全国住院病人抽样调查(2016-2021 年)的数据。研究纳入了接受心肺复苏的 OHCA 住院成人患者。多变量分析评估了姑息治疗咨询与非终末期和终末期 OHCA 住院治疗结果之间的关联,并对人口统计学、医院特征和合并症进行了调整:在 488,700 例 OHCA 住院患者中,姑息关怀咨询与非终末期住院患者较低的侵入性程序几率相关,包括经皮冠状动脉介入治疗(PCI)(aOR 0.30,95 % CI 0.25-0.36)、机械循环支持(aOR 0.54,95 % CI 0.44-0.68)、永久起搏器(aOR 0.27,95 % CI 0.20-0.37)、植入式心律转复除颤器(aOR 0.22,95 % CI 0.16-0.31)和心脏复律(aOR 0.62,95 % CI 0.55-0.70)。在末期住院治疗中,姑息治疗与较低的 PCI(aOR 0.78,95 % CI 0.70-0.87)和心脏电复律(aOR 0.91,95 % CI 0.85-0.97)几率相关,但与较高的治疗性低温(aOR 3.12,95 % CI 2.72-3.59)、胃造瘘(aOR 1.22,95 % CI 1.05-1.41)和肾脏替代治疗(aOR 1.19,95 % CI 1.12-1.26)几率相关。姑息治疗与两个亚组中较高的DNR使用率和较低的非终末期住院费用相关,但与较高的终末期住院费用相关:结论:在 OHCA 患者中,姑息治疗咨询与侵入性手术、DNR 使用率和住院费用的差异有关,这些差异因存活状况而异。
{"title":"Palliative care consultation in patients hospitalized with out-of-hospital cardiac arrest: Impact on invasive procedures, do-not-resuscitate orders, and healthcare costs.","authors":"Abdilahi Mohamoud, Nadhem Abdallah, Abdirahman Wardhere, Mahmoud Ismayl","doi":"10.1016/j.carrev.2024.08.003","DOIUrl":"https://doi.org/10.1016/j.carrev.2024.08.003","url":null,"abstract":"<p><strong>Background: </strong>The impact of palliative care consultation on the management and outcomes of patients hospitalized with out-of-hospital cardiac arrest (OHCA) remains poorly understood. This study examined associations between palliative care consultation and in-hospital outcomes of patients hospitalized with OHCA, stratified by survival status.</p><p><strong>Method: </strong>This cross-sectional study used data from the National Inpatient Sample (2016-2021). Adult patients hospitalized with OHCA who received cardiopulmonary resuscitation were included. Multivariable analyses assessed associations between palliative care consultation and outcomes in non-terminal and terminal OHCA hospitalizations, adjusting for demographics, hospital characteristics, and comorbidities.</p><p><strong>Results: </strong>Among 488,700 OHCA hospitalizations, palliative care consultation was associated with lower odds of invasive procedures in non-terminal hospitalizations, including percutaneous coronary intervention (PCI) (aOR 0.30, 95 % CI 0.25-0.36), mechanical circulatory support (aOR 0.54, 95 % CI 0.44-0.68), permanent pacemaker (aOR 0.27, 95 % CI 0.20-0.37), implantable cardioverter defibrillator insertion (aOR 0.22, 95 % CI 0.16-0.31), and cardioversion (aOR 0.62, 95 % CI 0.55-0.70). In terminal hospitalizations, palliative care was associated with lower odds of PCI (aOR 0.78, 95 % CI 0.70-0.87) and cardioversion (aOR 0.91, 95 % CI 0.85-0.97), but higher odds of therapeutic hypothermia (aOR 3.12, 95 % CI 2.72-3.59), gastrostomy (aOR 1.22, 95 % CI 1.05-1.41), and renal replacement therapy (aOR 1.19, 95 % CI 1.12-1.26). Palliative care was associated with higher DNR utilization in both subgroups and lower hospital costs in non-terminal hospitalizations but higher costs in terminal hospitalizations.</p><p><strong>Conclusion: </strong>Palliative care consultation in OHCA is associated with differences in invasive procedures, DNR utilization, and hospital costs, varying by survival status.</p>","PeriodicalId":47657,"journal":{"name":"Cardiovascular Revascularization Medicine","volume":" ","pages":""},"PeriodicalIF":1.6,"publicationDate":"2024-08-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142037294","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Safety and efficacy of covered stent grafts in the treatment of emergent access related complications. 有盖支架移植物治疗紧急入路相关并发症的安全性和有效性。
IF 1.6 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-08-16 DOI: 10.1016/j.carrev.2024.08.011
Michael Wilderman, Kazuya Tateishi, David O'Connor, Sophia Simonian, Anjali Ratnathicam, Kristen Cook, Lucius De Gregorio, Hosam Hmoud, Joseph De Gregorio

Background: Large bore percutaneous access is becoming increasingly common. Parallel to this, we observe an increase in vascular access site complications such as bleeding, dissection, thrombosis or pseudo-aneurysms. This study was aimed to evaluate safety and efficacy of covered stent grafts for fixing large bore vascular access injuries.

Methods: A total of 147 Viabahn or Viabahn VBX (WL Gore) stent grafts which were placed across the inguinal ligament in emergent settings in 136 patients, were retrospectively analyzed. The two endpoints were the technical success rate, defined by complete arterial repair, and long-term stent graft patency. We also looked at the need for open conversion, wound infections, and in hospital and 30-day mortality. We followed the patients using duplex ultrasound and computed tomography angiogram to assess for arterial patency, freedom from intervention, stent kinking and clinical symptoms.

Results: 30 Viabahn and 117 Viabahn VBX (WL Gore) stent grafts were placed in the distal external iliac artery and into the proximal common femoral artery of 136 patients. Indications for intervention were bleeding in 92 patients (68 %), flow limiting dissection in 41 patients (30 %) and symptomatic AVF in 3 patients (2 %). Primary technical success rate was 100 %. Limited 3-year follow up (101/136 patients) showed 99 % patency with no evidence of stent fracture, stenosis or kinking except in one patient who needed target lesion revascularization due to neointimal hyperplasia.

Conclusions: Covered stent grafts can be placed safely, efficiently, and effectively in the distal external iliac and common femoral arteries across the inguinal ligament. These stent grafts can be used as an alternative therapeutic option to open surgery in patients with large bore vascular access injuries.

背景:大口径经皮入路越来越普遍。与此同时,我们发现血管通路部位的并发症也在增加,如出血、夹层、血栓或假性动脉瘤。本研究旨在评估覆盖支架移植物固定大口径血管通路损伤的安全性和有效性:回顾性分析了 136 名患者的 147 个 Viabahn 或 Viabahn VBX(WL 戈尔公司)支架移植物,这些移植物都是在紧急情况下穿过腹股沟韧带植入的。两个终点分别是技术成功率(以动脉完全修复为标准)和支架移植物的长期通畅率。我们还考察了患者是否需要进行开放性转流、伤口感染以及住院和 30 天死亡率。我们使用双相超声波和计算机断层扫描血管造影术对患者进行随访,以评估动脉通畅度、无介入治疗、支架扭结和临床症状:在136名患者的髂外动脉远端和股总动脉近端分别植入了30枚Viabahn和117枚Viabahn VBX(WL戈尔)支架移植物。92 名患者(68%)的介入指征为出血,41 名患者(30%)为血流受限夹层,3 名患者(2%)为症状性动静脉瘘。初次技术成功率为 100%。为期3年的有限随访(101/136例患者)显示,支架通畅率为99%,无支架断裂、狭窄或扭结迹象,只有一名患者因新血管内膜增生而需要进行靶病变血管再通手术:结论:覆盖支架移植物可以安全、高效、有效地穿过腹股沟韧带植入髂外动脉和股总动脉远端。这些支架移植物可作为大口径血管通路损伤患者开放手术的替代治疗方案。
{"title":"Safety and efficacy of covered stent grafts in the treatment of emergent access related complications.","authors":"Michael Wilderman, Kazuya Tateishi, David O'Connor, Sophia Simonian, Anjali Ratnathicam, Kristen Cook, Lucius De Gregorio, Hosam Hmoud, Joseph De Gregorio","doi":"10.1016/j.carrev.2024.08.011","DOIUrl":"https://doi.org/10.1016/j.carrev.2024.08.011","url":null,"abstract":"<p><strong>Background: </strong>Large bore percutaneous access is becoming increasingly common. Parallel to this, we observe an increase in vascular access site complications such as bleeding, dissection, thrombosis or pseudo-aneurysms. This study was aimed to evaluate safety and efficacy of covered stent grafts for fixing large bore vascular access injuries.</p><p><strong>Methods: </strong>A total of 147 Viabahn or Viabahn VBX (WL Gore) stent grafts which were placed across the inguinal ligament in emergent settings in 136 patients, were retrospectively analyzed. The two endpoints were the technical success rate, defined by complete arterial repair, and long-term stent graft patency. We also looked at the need for open conversion, wound infections, and in hospital and 30-day mortality. We followed the patients using duplex ultrasound and computed tomography angiogram to assess for arterial patency, freedom from intervention, stent kinking and clinical symptoms.</p><p><strong>Results: </strong>30 Viabahn and 117 Viabahn VBX (WL Gore) stent grafts were placed in the distal external iliac artery and into the proximal common femoral artery of 136 patients. Indications for intervention were bleeding in 92 patients (68 %), flow limiting dissection in 41 patients (30 %) and symptomatic AVF in 3 patients (2 %). Primary technical success rate was 100 %. Limited 3-year follow up (101/136 patients) showed 99 % patency with no evidence of stent fracture, stenosis or kinking except in one patient who needed target lesion revascularization due to neointimal hyperplasia.</p><p><strong>Conclusions: </strong>Covered stent grafts can be placed safely, efficiently, and effectively in the distal external iliac and common femoral arteries across the inguinal ligament. These stent grafts can be used as an alternative therapeutic option to open surgery in patients with large bore vascular access injuries.</p>","PeriodicalId":47657,"journal":{"name":"Cardiovascular Revascularization Medicine","volume":" ","pages":""},"PeriodicalIF":1.6,"publicationDate":"2024-08-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142019112","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Conduction dynamics over time after transcatheter aortic valve replacement: An expert review. 经导管主动脉瓣置换术后随时间变化的传导动力学:专家点评。
IF 1.6 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-08-16 DOI: 10.1016/j.carrev.2024.08.005
Herbert G Kroon, Thijmen Hokken, Maarten van Wiechen, Joris F W Ooms, Lennart van Gils, Isabella Kardys, Joost Daemen, Peter P T De Jaegere, Rutger-Jan Nuis, Nicolas M Van Mieghem

New conduction disorders remain a frequent complication in current transcatheter aortic valve replacement (TAVR) era. Left bundle branch block (LBBB) occurs early in about 20-30 % of TAVR-patients, persists at 1 month in about 35-45 % of cases and will likely remain thereafter. Third-degree atrioventricular block (AV3B) affects approximately 15 % of patients. Pacemaker dependency gradually decreases throughout follow-up and approximately 25-35 % of patients remain pacemaker dependent at one year. We aimed to review what is currently known about the dynamics of acquired conduction disorders, including extraction of predictors, and how to interpret these dynamics in light of an early discharge policy.

在目前的经导管主动脉瓣置换术(TAVR)时代,新的传导障碍仍然是一种常见的并发症。左束支传导阻滞(LBBB)在大约20%-30%的TAVR患者中早期出现,大约35%-45%的病例在1个月后持续存在,并且可能会一直存在。约15%的患者会出现三度房室传导阻滞(AV3B)。起搏器依赖性在随访过程中逐渐降低,大约 25%-35% 的患者在一年后仍然依赖起搏器。我们旨在回顾目前对获得性传导障碍动态变化的了解,包括提取预测因素,以及如何根据早期出院政策解释这些动态变化。
{"title":"Conduction dynamics over time after transcatheter aortic valve replacement: An expert review.","authors":"Herbert G Kroon, Thijmen Hokken, Maarten van Wiechen, Joris F W Ooms, Lennart van Gils, Isabella Kardys, Joost Daemen, Peter P T De Jaegere, Rutger-Jan Nuis, Nicolas M Van Mieghem","doi":"10.1016/j.carrev.2024.08.005","DOIUrl":"https://doi.org/10.1016/j.carrev.2024.08.005","url":null,"abstract":"<p><p>New conduction disorders remain a frequent complication in current transcatheter aortic valve replacement (TAVR) era. Left bundle branch block (LBBB) occurs early in about 20-30 % of TAVR-patients, persists at 1 month in about 35-45 % of cases and will likely remain thereafter. Third-degree atrioventricular block (AV3B) affects approximately 15 % of patients. Pacemaker dependency gradually decreases throughout follow-up and approximately 25-35 % of patients remain pacemaker dependent at one year. We aimed to review what is currently known about the dynamics of acquired conduction disorders, including extraction of predictors, and how to interpret these dynamics in light of an early discharge policy.</p>","PeriodicalId":47657,"journal":{"name":"Cardiovascular Revascularization Medicine","volume":" ","pages":""},"PeriodicalIF":1.6,"publicationDate":"2024-08-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142298650","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Aortic balloon valvuloplasty outcome according to calcium distribution and valve geometry - The ABCD study. 根据钙分布和瓣膜几何形状得出的主动脉球囊瓣膜成形术结果--ABCD 研究。
IF 1.6 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-08-16 DOI: 10.1016/j.carrev.2024.08.004
Gianni Dall'Ara, Sara Piciucchi, Carolina Moretti, Caterina Cavazza, Miriam Compagnone, Giuseppe Guerrieri, Simone Grotti, Daniela Spartà, Roberto Carletti, Elisabetta Fabbri, Emanuela Giampalma, Andrea Santarelli, Filippo Ottani, Marco Balducelli, Francesco Saia, Fabio Felice Tarantino, Marcello Galvani

Background: There is little data on the outcome of balloon aortic valvuloplasty (BAV) in relation to valve dimensions and calcification patterns. The procedure is not standardized, particularly the choice of balloon size.

Methods: This retrospective multicenter study focused on BAV efficacy and safety by analyzing the relationship between balloon size, annulus geometry (i.e., diameters, perimeter, and area), and calcification patterns (total burden and calcium distribution over each individual leaflet). From March 2018 to March 2023, all consecutive patients who underwent clinically indicated BAV and ECG-gated multidetector computed tomography of the aorta were included, except those with a bicuspid valve. Calcium score was calculated on contrast-enhanced images based on a luminal attenuation threshold of +100 HU.

Results: One hundred and fifteen patients were included. Procedural success was 82.6 %. The balloon-to-annulus ratio (BAR) relative to diameter, perimeter, and area was higher in patients with successful BAV. Patients with unsuccessful BAV had a significantly higher aortic valve calcium burden. The complication rate was 4.3 % and there was no association with valve geometry or calcium burden. A trend towards a reduced complication rate was found as calcium asymmetry increased. BAR minimum annulus diameter was the best parameter in predicting procedural success, with a cut-off at 0.85.

Conclusions: BAV efficacy is correlated directly with balloon size in relation to annulus dimension and inversely with total calcium burden. The minimum diameter of the valve may be adopted as a reference for balloon sizing.

背景:关于球囊主动脉瓣成形术(BAV)的结果与瓣膜尺寸和钙化模式的关系的数据很少。该手术没有标准化,尤其是球囊大小的选择:这项回顾性多中心研究通过分析球囊大小、瓣环几何形状(即直径、周长和面积)和钙化模式(总负荷和钙在每个瓣叶的分布)之间的关系,重点研究主动脉瓣成形术的疗效和安全性。从 2018 年 3 月至 2023 年 3 月,所有接受有临床指征的 BAV 和心电图门控主动脉多矢量计算机断层扫描的连续患者均被纳入研究,但双尖瓣患者除外。根据+100 HU的管腔衰减阈值计算造影剂增强图像的钙化评分:结果:共纳入 115 名患者。手术成功率为 82.6%。相对于直径、周长和面积,成功 BAV 患者的球囊与窦腔比率(BAR)更高。BAV手术不成功的患者主动脉瓣钙负荷明显较高。并发症发生率为 4.3%,与瓣膜几何形状或钙质负荷无关。随着钙质不对称程度的增加,并发症发生率呈下降趋势。BAR最小瓣环直径是预测手术成功的最佳参数,临界值为0.85:BAV疗效与球囊大小和瓣环尺寸直接相关,而与总钙负荷成反比。瓣膜的最小直径可作为球囊大小的参考。
{"title":"Aortic balloon valvuloplasty outcome according to calcium distribution and valve geometry - The ABCD study.","authors":"Gianni Dall'Ara, Sara Piciucchi, Carolina Moretti, Caterina Cavazza, Miriam Compagnone, Giuseppe Guerrieri, Simone Grotti, Daniela Spartà, Roberto Carletti, Elisabetta Fabbri, Emanuela Giampalma, Andrea Santarelli, Filippo Ottani, Marco Balducelli, Francesco Saia, Fabio Felice Tarantino, Marcello Galvani","doi":"10.1016/j.carrev.2024.08.004","DOIUrl":"https://doi.org/10.1016/j.carrev.2024.08.004","url":null,"abstract":"<p><strong>Background: </strong>There is little data on the outcome of balloon aortic valvuloplasty (BAV) in relation to valve dimensions and calcification patterns. The procedure is not standardized, particularly the choice of balloon size.</p><p><strong>Methods: </strong>This retrospective multicenter study focused on BAV efficacy and safety by analyzing the relationship between balloon size, annulus geometry (i.e., diameters, perimeter, and area), and calcification patterns (total burden and calcium distribution over each individual leaflet). From March 2018 to March 2023, all consecutive patients who underwent clinically indicated BAV and ECG-gated multidetector computed tomography of the aorta were included, except those with a bicuspid valve. Calcium score was calculated on contrast-enhanced images based on a luminal attenuation threshold of +100 HU.</p><p><strong>Results: </strong>One hundred and fifteen patients were included. Procedural success was 82.6 %. The balloon-to-annulus ratio (BAR) relative to diameter, perimeter, and area was higher in patients with successful BAV. Patients with unsuccessful BAV had a significantly higher aortic valve calcium burden. The complication rate was 4.3 % and there was no association with valve geometry or calcium burden. A trend towards a reduced complication rate was found as calcium asymmetry increased. BAR minimum annulus diameter was the best parameter in predicting procedural success, with a cut-off at 0.85.</p><p><strong>Conclusions: </strong>BAV efficacy is correlated directly with balloon size in relation to annulus dimension and inversely with total calcium burden. The minimum diameter of the valve may be adopted as a reference for balloon sizing.</p>","PeriodicalId":47657,"journal":{"name":"Cardiovascular Revascularization Medicine","volume":" ","pages":""},"PeriodicalIF":1.6,"publicationDate":"2024-08-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142009703","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Microcirculatory status after intravascular lithotripsy: The MARVEL study. 血管内碎石术后的微循环状态:MARVEL 研究。
IF 1.6 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-08-16 DOI: 10.1016/j.carrev.2024.08.009
Frederic Bouisset, Javier Escaned, Daniel Munhoz, Takuya Mizukami, Ruiko Seki, Carlos H Salazar, Jeroen Sonck, Nieves Gonzalo, Bernard De Bruyne, Carlos Collet
{"title":"Microcirculatory status after intravascular lithotripsy: The MARVEL study.","authors":"Frederic Bouisset, Javier Escaned, Daniel Munhoz, Takuya Mizukami, Ruiko Seki, Carlos H Salazar, Jeroen Sonck, Nieves Gonzalo, Bernard De Bruyne, Carlos Collet","doi":"10.1016/j.carrev.2024.08.009","DOIUrl":"https://doi.org/10.1016/j.carrev.2024.08.009","url":null,"abstract":"","PeriodicalId":47657,"journal":{"name":"Cardiovascular Revascularization Medicine","volume":" ","pages":""},"PeriodicalIF":1.6,"publicationDate":"2024-08-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142056905","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Risk factors for early mortality following transcatheter edge-to-edge repair of mitral regurgitation. 经导管边缘到边缘二尖瓣反流修复术后早期死亡率的风险因素。
IF 1.6 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-08-15 DOI: 10.1016/j.carrev.2024.08.001
Yong-Hao Yeo, Jia-Yean Thong, Min-Choon Tan, Qi-Xuan Ang, Boon-Jian San, Bryan E-Xin Tan, Arka Chatterjee, Kwan Lee

Background: While transcatheter edge-to-edge repair (TEER) with MitraClip is increasingly used, data on the risk stratification for assessing early mortality after this procedure are scarce.

Objective: This study aimed to assess early mortality and analyze the risk factors of early mortality among patients who underwent TEER.

Methods: Using the all-payer, nationally representative Nationwide Readmissions Database, our study included patients aged 18 years or older who had TEER between January 2017 and November 2020. We categorized the cohort into two groups depending on the occurrence of early mortality (death within 30 days after the procedure). Based on the ICD-10, we identified the trend of early mortality after TEER and further analyzed the risk factors associated with early mortality.

Results: A total of 15,931 patients who had TEER were included; 292 (1.8 %) with early mortality and 15,639 (98.2 %) without. There was a decreasing trend in early mortality from 2.8 % in the first quarter of 2017 to 1.2 % in the fourth quarter of 2020, but it was not statistically significant (p = 0.18). In multivariable analysis, the independent risk factors for early mortality were chronic kidney disease not requiring dialysis (adjusted odds ratio [aOR]: 1.57; 95 % confidence interval [CI]: 1.11-2.22, p = 0.01), end-stage renal disease (aOR: 2.34; CI: 1.44-3.79, p < 0.01), chronic liver disease (aOR: 4.90; CI: 3.29-7.29, p < 0.01), coagulation disorder (aOR: 3.42; CI: 2.35-5.03, p < 0.01), systolic heart failure (aOR: 2.81; CI: 1.34-5.90, p < 0.01), diastolic heart failure (aOR: 2.69; CI: 1.24-5.84, p = 0.01) and unspecified heart failure (aOR: 3.23; CI: 1.49-7.01, p < 0.01). Among those who died during 30-day readmission following TEER, the most common cardiac cause and non-cardiac-cause of readmission were heart failure (18.2 %) and infection (26.6 %), respectively.

Conclusion: The early mortality following TEER was low at 1.8 %. The independent risk factors associated with early mortality were chronic kidney disease (including end-stage renal disease), chronic liver disease, coagulation disorder, and heart failure (both systolic and diastolic).

背景:虽然使用MitraClip进行经导管边缘到边缘修补术(TEER)的患者越来越多,但评估该手术后早期死亡率的风险分层数据却很少:本研究旨在评估接受 TEER 患者的早期死亡率,并分析早期死亡率的风险因素:我们的研究使用了具有全国代表性的全国再入院数据库(Nationwide Readmissions Database),纳入了在 2017 年 1 月至 2020 年 11 月期间接受 TEER 的 18 岁或以上患者。我们根据早期死亡(术后 30 天内死亡)的发生率将队列分为两组。根据ICD-10,我们确定了TEER术后早期死亡的趋势,并进一步分析了与早期死亡相关的风险因素:共纳入 15,931 例 TEER 患者,其中 292 例(1.8%)有早期死亡,15,639 例(98.2%)无早期死亡。早期死亡率呈下降趋势,从2017年第一季度的2.8%降至2020年第四季度的1.2%,但无统计学意义(P = 0.18)。在多变量分析中,早期死亡的独立风险因素是不需要透析的慢性肾病(调整后的几率比 [aOR]:1.57; 95 % 置信区间 [CI]:1.11-2.22,P = 0.01)、终末期肾病(aOR:2.34;CI:1.44-3.79,P = 0.01)、急性肾衰竭(aOR:2.34;CI:1.44-3.79,P = 0.01TEER 的早期死亡率较低,仅为 1.8%。与早期死亡率相关的独立风险因素是慢性肾病(包括终末期肾病)、慢性肝病、凝血功能障碍和心力衰竭(收缩期和舒张期)。
{"title":"Risk factors for early mortality following transcatheter edge-to-edge repair of mitral regurgitation.","authors":"Yong-Hao Yeo, Jia-Yean Thong, Min-Choon Tan, Qi-Xuan Ang, Boon-Jian San, Bryan E-Xin Tan, Arka Chatterjee, Kwan Lee","doi":"10.1016/j.carrev.2024.08.001","DOIUrl":"https://doi.org/10.1016/j.carrev.2024.08.001","url":null,"abstract":"<p><strong>Background: </strong>While transcatheter edge-to-edge repair (TEER) with MitraClip is increasingly used, data on the risk stratification for assessing early mortality after this procedure are scarce.</p><p><strong>Objective: </strong>This study aimed to assess early mortality and analyze the risk factors of early mortality among patients who underwent TEER.</p><p><strong>Methods: </strong>Using the all-payer, nationally representative Nationwide Readmissions Database, our study included patients aged 18 years or older who had TEER between January 2017 and November 2020. We categorized the cohort into two groups depending on the occurrence of early mortality (death within 30 days after the procedure). Based on the ICD-10, we identified the trend of early mortality after TEER and further analyzed the risk factors associated with early mortality.</p><p><strong>Results: </strong>A total of 15,931 patients who had TEER were included; 292 (1.8 %) with early mortality and 15,639 (98.2 %) without. There was a decreasing trend in early mortality from 2.8 % in the first quarter of 2017 to 1.2 % in the fourth quarter of 2020, but it was not statistically significant (p = 0.18). In multivariable analysis, the independent risk factors for early mortality were chronic kidney disease not requiring dialysis (adjusted odds ratio [aOR]: 1.57; 95 % confidence interval [CI]: 1.11-2.22, p = 0.01), end-stage renal disease (aOR: 2.34; CI: 1.44-3.79, p < 0.01), chronic liver disease (aOR: 4.90; CI: 3.29-7.29, p < 0.01), coagulation disorder (aOR: 3.42; CI: 2.35-5.03, p < 0.01), systolic heart failure (aOR: 2.81; CI: 1.34-5.90, p < 0.01), diastolic heart failure (aOR: 2.69; CI: 1.24-5.84, p = 0.01) and unspecified heart failure (aOR: 3.23; CI: 1.49-7.01, p < 0.01). Among those who died during 30-day readmission following TEER, the most common cardiac cause and non-cardiac-cause of readmission were heart failure (18.2 %) and infection (26.6 %), respectively.</p><p><strong>Conclusion: </strong>The early mortality following TEER was low at 1.8 %. The independent risk factors associated with early mortality were chronic kidney disease (including end-stage renal disease), chronic liver disease, coagulation disorder, and heart failure (both systolic and diastolic).</p>","PeriodicalId":47657,"journal":{"name":"Cardiovascular Revascularization Medicine","volume":" ","pages":""},"PeriodicalIF":1.6,"publicationDate":"2024-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142019168","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The impact of stress testing to guide PCI in patients with chronic coronary disease. 压力测试对慢性冠心病患者PCI的指导作用。
IF 1.6 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-08-15 DOI: 10.1016/j.carrev.2024.08.010
Garry W Hamilton, Anoop N Koshy, Diem Dinh, Angela Brennan, Julian Yeoh, Matias B Yudi, Mark Horrigan, Christopher M Reid, Dion Stub, William Chan, Ernesto Oqueli, Melanie Freeman, Chin Hiew, Andrew Ajani, Omar Farouque, David J Clark

Background: Guidelines and international appropriate use criteria increasingly endorse non-invasive stress testing to evaluate patients with suspected chronic coronary disease (CCD). We sought to review the real-world utilisation of non-invasive stress testing and investigate whether their use prior to PCI associates with outcomes in patients with CCD.

Methods: Consecutive patients from a multicentre registry who underwent PCI for CCD between 2006 and 2018 were included. Clinical characteristics and outcomes were stratified according to whether stress testing was performed prior to PCI (stress vs no-stress groups). The primary outcome was 3-year all-cause mortality.

Results: Among the 8251 patients included, 4970 (60.2 %) underwent pre-PCI stress testing and this proportion increased over time (p-for-trend<0.001). The stress group had a lower prevalence of prior revascularization, myocardial infarction, or heart failure, and a lower incidence of triple vessel disease, in stent re-stenosis, and ACC/AHA class B2/C lesions (all p < 0.001). When comparing post-procedural outcomes, the stress group had lower rates of arrhythmia (1.5 % vs 2.6 %, p = 0.001), new heart failure (0.2 % vs 0.8 %, p = 0.001), renal impairment, and a shorter length of stay (1.6 vs 2.1 days, p < 0.001). Mortality at 3-years was lower in those undergoing PCI following stress testing (5.8 % vs 8.8 %, p < 0.001). After adjusting for key clinical variables, stress guided revascularization was associated with a significantly lower risk of 3-year mortality (adjusted Hazard Ratio 0.77, 95 % CI 0.64-0.92).

Conclusions: In patients with CCD, PCI guided by non-invasive stress testing is increasingly utilized and associated with improved survival. Further studies are necessary to investigate whether this results from differences in patient characteristics, optimized patient selection, or refined choice of target vessel.

背景:越来越多的指南和国际适当使用标准认可用无创压力测试来评估疑似慢性冠状动脉疾病(CCD)患者。我们试图回顾无创压力测试在现实世界中的使用情况,并研究PCI术前使用无创压力测试是否与CCD患者的预后有关:方法:纳入2006年至2018年期间因CCD接受PCI治疗的多中心登记的连续患者。根据 PCI 前是否进行压力测试对临床特征和预后进行分层(压力组与无压力组)。主要结果是3年全因死亡率:结果:在纳入的 8251 例患者中,4970 例(60.2%)接受了 PCI 前压力测试,且这一比例随着时间的推移而增加(p-for-trend):在CCD患者中,越来越多的患者在无创压力测试的指导下进行PCI,这与生存率的提高有关。有必要开展进一步的研究,以探讨患者特征的差异、患者选择的优化或靶血管选择的改进是否会导致这一结果。
{"title":"The impact of stress testing to guide PCI in patients with chronic coronary disease.","authors":"Garry W Hamilton, Anoop N Koshy, Diem Dinh, Angela Brennan, Julian Yeoh, Matias B Yudi, Mark Horrigan, Christopher M Reid, Dion Stub, William Chan, Ernesto Oqueli, Melanie Freeman, Chin Hiew, Andrew Ajani, Omar Farouque, David J Clark","doi":"10.1016/j.carrev.2024.08.010","DOIUrl":"https://doi.org/10.1016/j.carrev.2024.08.010","url":null,"abstract":"<p><strong>Background: </strong>Guidelines and international appropriate use criteria increasingly endorse non-invasive stress testing to evaluate patients with suspected chronic coronary disease (CCD). We sought to review the real-world utilisation of non-invasive stress testing and investigate whether their use prior to PCI associates with outcomes in patients with CCD.</p><p><strong>Methods: </strong>Consecutive patients from a multicentre registry who underwent PCI for CCD between 2006 and 2018 were included. Clinical characteristics and outcomes were stratified according to whether stress testing was performed prior to PCI (stress vs no-stress groups). The primary outcome was 3-year all-cause mortality.</p><p><strong>Results: </strong>Among the 8251 patients included, 4970 (60.2 %) underwent pre-PCI stress testing and this proportion increased over time (p-for-trend<0.001). The stress group had a lower prevalence of prior revascularization, myocardial infarction, or heart failure, and a lower incidence of triple vessel disease, in stent re-stenosis, and ACC/AHA class B2/C lesions (all p < 0.001). When comparing post-procedural outcomes, the stress group had lower rates of arrhythmia (1.5 % vs 2.6 %, p = 0.001), new heart failure (0.2 % vs 0.8 %, p = 0.001), renal impairment, and a shorter length of stay (1.6 vs 2.1 days, p < 0.001). Mortality at 3-years was lower in those undergoing PCI following stress testing (5.8 % vs 8.8 %, p < 0.001). After adjusting for key clinical variables, stress guided revascularization was associated with a significantly lower risk of 3-year mortality (adjusted Hazard Ratio 0.77, 95 % CI 0.64-0.92).</p><p><strong>Conclusions: </strong>In patients with CCD, PCI guided by non-invasive stress testing is increasingly utilized and associated with improved survival. Further studies are necessary to investigate whether this results from differences in patient characteristics, optimized patient selection, or refined choice of target vessel.</p>","PeriodicalId":47657,"journal":{"name":"Cardiovascular Revascularization Medicine","volume":" ","pages":""},"PeriodicalIF":1.6,"publicationDate":"2024-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142037295","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Transcatheter Interventions for Acute Pulmonary Embolism in Patients With Underlying Malignancy: A Propensity-Matched Nationwide Study 经导管介入治疗恶性肿瘤患者的急性肺栓塞:倾向匹配全国性研究
IF 1.6 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-08-01 DOI: 10.1016/j.carrev.2024.04.113
Shafaqat Ali , Manoj Kumar , Faryal Farooq , Muhammad Sultan , Malalai Manan , Hameem Changezi , Ahmad Munir , Tarek Helmy
{"title":"Transcatheter Interventions for Acute Pulmonary Embolism in Patients With Underlying Malignancy: A Propensity-Matched Nationwide Study","authors":"Shafaqat Ali ,&nbsp;Manoj Kumar ,&nbsp;Faryal Farooq ,&nbsp;Muhammad Sultan ,&nbsp;Malalai Manan ,&nbsp;Hameem Changezi ,&nbsp;Ahmad Munir ,&nbsp;Tarek Helmy","doi":"10.1016/j.carrev.2024.04.113","DOIUrl":"10.1016/j.carrev.2024.04.113","url":null,"abstract":"","PeriodicalId":47657,"journal":{"name":"Cardiovascular Revascularization Medicine","volume":"65 ","pages":"Pages 50-51"},"PeriodicalIF":1.6,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141949797","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Cardiovascular Revascularization Medicine
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1